1. Home
  2. ATHA vs RCG Comparison

ATHA vs RCG Comparison

Compare ATHA & RCG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ATHA
  • RCG
  • Stock Information
  • Founded
  • ATHA 2011
  • RCG 1994
  • Country
  • ATHA United States
  • RCG United States
  • Employees
  • ATHA N/A
  • RCG N/A
  • Industry
  • ATHA Medicinal Chemicals and Botanical Products
  • RCG Investment Managers
  • Sector
  • ATHA Health Care
  • RCG Finance
  • Exchange
  • ATHA Nasdaq
  • RCG Nasdaq
  • Market Cap
  • ATHA 16.1M
  • RCG 18.2M
  • IPO Year
  • ATHA 2020
  • RCG N/A
  • Fundamental
  • Price
  • ATHA $4.11
  • RCG $2.60
  • Analyst Decision
  • ATHA
  • RCG
  • Analyst Count
  • ATHA 0
  • RCG 0
  • Target Price
  • ATHA N/A
  • RCG N/A
  • AVG Volume (30 Days)
  • ATHA 27.3K
  • RCG 5.9K
  • Earning Date
  • ATHA 11-06-2025
  • RCG 01-01-0001
  • Dividend Yield
  • ATHA N/A
  • RCG 0.98%
  • EPS Growth
  • ATHA N/A
  • RCG N/A
  • EPS
  • ATHA N/A
  • RCG N/A
  • Revenue
  • ATHA N/A
  • RCG N/A
  • Revenue This Year
  • ATHA N/A
  • RCG N/A
  • Revenue Next Year
  • ATHA N/A
  • RCG N/A
  • P/E Ratio
  • ATHA N/A
  • RCG N/A
  • Revenue Growth
  • ATHA N/A
  • RCG N/A
  • 52 Week Low
  • ATHA $2.20
  • RCG $1.52
  • 52 Week High
  • ATHA $8.26
  • RCG $1.90
  • Technical
  • Relative Strength Index (RSI)
  • ATHA 59.40
  • RCG 50.81
  • Support Level
  • ATHA $3.95
  • RCG $2.50
  • Resistance Level
  • ATHA $4.50
  • RCG $2.66
  • Average True Range (ATR)
  • ATHA 0.24
  • RCG 0.07
  • MACD
  • ATHA -0.05
  • RCG -0.00
  • Stochastic Oscillator
  • ATHA 55.81
  • RCG 71.43

About ATHA Athira Pharma Inc.

Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.

About RCG RENN Fund Inc

RENN Fund Inc is active in the financial services domain. It is a a registered, non-diversified, closed-end management investment company formed to provide return through capital appreciation and income by a long-term, value-oriented investment process that invests in a wide variety of financial instruments, including but not limited to, common stocks, fixed-income securities including convertible and non-convertible debt securities or loans, distressed debt, warrants, and preferred stock, exchange-traded funds and exchange-traded notes, and other instruments. It invests in various industries, including communication services, surgical and medical instruments and apparatus, oil and gas, medical chemicals, botanical products, etc.

Share on Social Networks: